Human Apolipoprotein A-I Natural Variants: Molecular Mechanisms Underlying Amyloidogenic Propensity

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Ramella, Nahuel A ^a,b   Schinella, Guillermo R ^b,c   Ferreira, Sergio T ^d   Prieto, Eduardo D ^a,b   Vela, María E ^e   Ríos, José Luis ^f   Tricerri, M Alejandra ^a,b   Rimoldi, Omar J ^a,b  

^a CONICET ^*  (Argentina)

^b UNIVERSIDAD NACIONAL DE LA PLATA   (Argentina)

^c Centro Científico y Tecnológico Consejo Nacional de Investigaciones Científicas y Técnicas   (Argentina)

^d FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^e INSTITUTO DE INVESTIGACIONES FISICOQUÍMICAS TEÓRICAS Y APLICADAS INIFTA   (Argentina)

^f UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; ARGININE; GLYCINE; ISOLEUCINE; LYSINE;

AMYLOIDOSIS; ANIMAL CELL; APOA 1 GENE; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FLUORESCENCE; GENE; GENE MUTATION; GENETIC VARIABILITY; INFLAMMATION; KIDNEY DYSFUNCTION; MACROPHAGE ACTIVATION; MOLECULAR MECHANICS; NONHUMAN; PATHOGENESIS; PH; POLYNEUROPATHY; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN STABILITY; PROTEIN STRUCTURE;

AMINO ACID SUBSTITUTION; AMYLOIDOGENIC PROTEINS; ANIMALS; APOLIPOPROTEIN A-I; CELL LINE; HUMANS; MACROPHAGES; MICE; MUTANT PROTEINS; PROTEIN FOLDING; PROTEIN MULTIMERIZATION; PROTEIN STABILITY; PROTEIN STRUCTURE, SECONDARY;

EID: 84865473248     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043755     Document Type: Article

References (58)

1. Westermark P, Benson MD, Buxbaum JN, Cohen AS, Frangione B, et al. (2007) A primer of amyloid nomenclature. Amyloid 14: 179-183.
2. Ferreira ST, De Felice FG, Chapeaurouge A, (2006) Metastable, partially folded states in the productive folding and in the misfolding and amyloid aggregation of proteins. Cell Biochem Biophys 44: 539-548.
3. Ferreira ST, Vieira MN, De Felice FG, (2007) Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. IUBMB Life 59: 332-345.
4. Saraiva MJ, (2001) Transthyretin amyloidosis: a tale of weak interactions. FEBS Lett 498: 201-203.
5. Hardy J, Selkoe DJ, (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356.
6. Eriksson M, Schonland S, Yumlu S, Hegenbart U, von Hutten H, et al. (2009) Hereditary apolipoprotein AI-associated amyloidosis in surgical pathology specimens: identification of three novel mutations in the APOA1 gene. J Mol Diagn 11: 257-262.
7. Kazama JJ, Maruyama H, Gejyo F, (2001) Reduction of circulating beta2-microglobulin level for the treatment of dialysis-related amyloidosis. Nephrol Dial Transplant 16 (Suppl 4): 31-35.
8. Ramella NA, Rimoldi OJ, Prieto ED, Schinella GR, Sanchez SA, et al. (2011) Human apolipoprotein A-I-derived amyloid: its association with atherosclerosis. PLoS One 6: e22532.
9. Curtiss LK, Valenta DT, Hime NJ, Rye KA, (2006) What is so special about apolipoprotein AI in reverse cholesterol transport?. Arterioscler Thromb Vasc Biol 26: 12-19.
10. Gregorini G, Izzi C, Obici L, Tardanico R, Rocken C, et al. (2005) Renal apolipoprotein A-I amyloidosis: a rare and usually ignored cause of hereditary tubulointerstitial nephritis. J Am Soc Nephrol 16: 3680-3686.
11. Vigushin DM, Gough J, Allan D, Alguacil A, Penner B, et al. (1994) Familial nephropathic systemic amyloidosis caused by apolipoprotein AI variant Arg26. Q J Med 87: 149-154.
12. Booth DR, Tan SY, Booth SE, Tennent GA, Hutchinson WL, et al. (1996) Hereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein AI gene. J Clin Invest 97: 2714-2721.
13. Obici L, Bellotti V, Mangione P, Stoppini M, Arbustini E, et al. (1999) The new apolipoprotein A-I variant leu(174) -> Ser causes hereditary cardiac amyloidosis, and the amyloid fibrils are constituted by the 93-residue N-terminal polypeptide. Am J Pathol 155: 695-702.
14. Hamidi AK, Liepnieks JJ, Nakamura M, Parker F, Benson MD, (1999) A novel apolipoprotein A-1 variant, Arg173Pro, associated with cardiac and cutaneous amyloidosis. Biochem Biophys Res Commun 257: 584-588.
15. Lachmann HJ, Booth DR, Booth SE, Bybee A, Gilbertson JA, et al. (2002) Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 346: 1786-1791.
16. Amarzguioui M, Mucchiano G, Haggqvist B, Westermark P, Kavlie A, et al. (1998) Extensive intimal apolipoprotein A1-derived amyloid deposits in a patient with an apolipoprotein A1 mutation. Biochem Biophys Res Commun 242: 534-539.
17. Van Allen MW, Frohlich JA, Davis JR, (1969) Inherited predisposition to generalized amyloidosis. Clinical and pathological study of a family with neuropathy, nephropathy, and peptic ulcer. Neurology 19: 10-25.
18. Soutar AK, Hawkins PN, Vigushin DM, Tennent GA, Booth SE, et al. (1992) Apolipoprotein AI mutation Arg-60 causes autosomal dominant amyloidosis. Proc Natl Acad Sci U S A 89: 7389-7393.
19. Petrlova J, Duong T, Cochran MC, Axelsson A, Morgelin M, et al. (2012) The fibrillogenic L178H variant of apolipoprotein A-I forms helical fibrils. J Lipid Res 53: 390-398.
20. Araki K, Sasaki J, Matsunaga A, Takada Y, Moriyama K, et al. (1994) Characterization of two new human apolipoprotein A-I variants: apolipoprotein A-I Tsushima (Trp-108->Arg) and A-I Hita (Ala-95->Asp). Biochim Biophys Acta 1214: 272-278.
21. Miettinen HE, Jauhiainen M, Gylling H, Ehnholm S, Palomaki A, et al. (1997) Apolipoprotein A-IFIN (Leu159->Arg) mutation affects lecithin cholesterol acyltransferase activation and subclass distribution of HDL but not cholesterol efflux from fibroblasts. Arterioscler Thromb Vasc Biol 17: 3021-3032.
22. Takada Y, Sasaki J, Ogata S, Nakanishi T, Ikehara Y, et al. (1990) Isolation and characterization of human apolipoprotein A-I Fukuoka (110 Glu--Lys). A novel apolipoprotein variant. Biochim Biophys Acta 1043: 169-176.
23. Tilly-Kiesi M, Lichtenstein AH, Ordovas JM, Dolnikowski G, Malmstrom R, et al. (1997) Subjects with ApoA-I(Lys107->0) exhibit enhanced fractional catabolic rate of ApoA-I in Lp(AI) and ApoA-II in Lp(AI with AII). Arterioscler Thromb Vasc Biol 17: 873-880.
24. Rader DJ, Gregg RE, Meng MS, Schaefer JR, Zech LA, et al. (1992) In vivo metabolism of a mutant apolipoprotein, apoA-IIowa, associated with hypoalphalipoproteinemia and hereditary systemic amyloidosis. J Lipid Res 33: 755-763.
25. Ryan RO, Forte TM, Oda MN, (2003) Optimized bacterial expression of human apolipoprotein A-I. Protein Expr Purif 27: 98-103.
26. Gonzalez MC, Toledo JD, Tricerri MA, Garda HA, (2008) The central type Y amphipathic alpha-helices of apolipoprotein AI are involved in the mobilization of intracellular cholesterol depots. Arch Biochem Biophys 473: 34-41.
27. Lakowicz JR (1986) Principles of fluorescence spectroscopy. New York: P. Press.
28. Chapeaurouge A, Johansson JS, Ferreira ST, (2001) Folding intermediates of a model three-helix bundle protein. Pressure and cold denaturation studies. J Biol Chem 276: 14861-14866.
29. Botelho MG, Gralle M, Oliveira CL, Torriani I, Ferreira ST, (2003) Folding and stability of the extracellular domain of the human amyloid precursor protein. J Biol Chem 278: 34259-34267.
30. Chapeaurouge A, Johansson JS, Ferreira ST, (2002) Folding of a de novo designed native-like four-helix bundle protein. J Biol Chem 277: 16478-16483.
31. Martins SM, Chapeaurouge A, Ferreira ST, (2003) Folding intermediates of the prion protein stabilized by hydrostatic pressure and low temperature. J Biol Chem 278: 50449-50455.
32. Jaureguiberry MS, Tricerri MA, Sanchez SA, Garda HA, Finarelli GS, et al. (2010) Membrane organization and regulation of cellular cholesterol homeostasis. J Membr Biol 234: 183-194.
33. De Felice FG, Houzel JC, Garcia-Abreu J, Louzada PR Jr, Afonso RC, et al. (2001) Inhibition of Alzheimer's disease beta-amyloid aggregation, neurotoxicity, and in vivo deposition by nitrophenols: implications for Alzheimer's therapy. Faseb J 15: 1297-1299.
34. Davidson WS, Arnvig-McGuire K, Kennedy A, Kosman J, Hazlett TL, et al. (1999) Structural organization of the N-terminal domain of apolipoprotein A-I: studies of tryptophan mutants. Biochemistry 38: 14387-14395.
35. Smoot AL, Panda M, Brazil BT, Buckle AM, Fersht AR, et al. (2001) The binding of bis-ANS to the isolated GroEL apical domain fragment induces the formation of a folding intermediate with increased hydrophobic surface not observed in tetradecameric GroEL. Biochemistry 40: 4484-4492.
36. Martins SM, Chapeaurouge A, Ferreira ST, (2002) Equilibrium unfolding and conformational plasticity of troponin I and T. Eur J Biochem. 269: 5484-5491.
37. Tricerri MA, Behling Agree AK, Sanchez SA, Jonas A, (2000) Characterization of apolipoprotein A-I structure using a cysteine-specific fluorescence probe. Biochemistry 39: 14682-14691.
38. Tricerri MA, Behling Agree AK, Sanchez SA, Bronski J, Jonas A, (2001) Arrangement of apolipoprotein A-I in reconstituted high-density lipoprotein disks: an alternative model based on fluorescence resonance energy transfer experiments. Biochemistry 40: 5065-5074.
39. Gursky O, Atkinson D, (1996) Thermal unfolding of human high-density apolipoprotein A-1: implications for a lipid-free molten globular state. Proc Natl Acad Sci U S A 93: 2991-2995.
40. Lagerstedt JO, Cavigiolio G, Roberts LM, Hong HS, Jin LW, et al. (2007) Mapping the structural transition in an amyloidogenic apolipoprotein A-I. Biochemistry 46: 9693-9699.
41. Munishkina LA, Fink AL, (2007) Fluorescence as a method to reveal structures and membrane-interactions of amyloidogenic proteins. Biochim Biophys Acta 1768: 1862-1885.
42. Hawe A, Sutter M, Jiskoot W, (2008) Extrinsic fluorescent dyes as tools for protein characterization. Pharm Res 25: 1487-1499.
43. LeVine H 3rd (1999) Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol. 309: 274-284.
44. Obici L, Franceschini G, Calabresi L, Giorgetti S, Stoppini M, et al. (2006) Structure, function and amyloidogenic propensity of apolipoprotein A-I. Amyloid 13: 191-205.
45. Lindstedt L, Saarinen J, Kalkkinen N, Welgus H, Kovanen PT, (1999) Matrix metalloproteinases-3,-7, and-12, but not-9, reduce high density lipoprotein-induced cholesterol efflux from human macrophage foam cells by truncation of the carboxyl terminus of apolipoprotein A-I. Parallel losses of pre-beta particles and the high affinity component of efflux. J Biol Chem 274: 22627-22634.
46. Klabunde T, Petrassi HM, Oza VB, Raman P, Kelly JW, et al. (2000) Rational design of potent human transthyretin amyloid disease inhibitors. Nat Struct Biol 7: 312-321.
47. Canet D, Sunde M, Last AM, Miranker A, Spencer A, et al. (1999) Mechanistic studies of the folding of human lysozyme and the origin of amyloidogenic behavior in its disease-related variants. Biochemistry 38: 6419-6427.
48. De Felice FG, Vieira MN, Meirelles MN, Morozova-Roche LA, Dobson CM, et al. (2004) Formation of amyloid aggregates from human lysozyme and its disease-associated variants using hydrostatic pressure. Faseb J 18: 1099-1101.
49. Vieira MN, Forny-Germano L, Saraiva LM, Sebollela A, Martinez AM, et al. (2007) Soluble oligomers from a non-disease related protein mimic Abeta-induced tau hyperphosphorylation and neurodegeneration. J Neurochem 103: 736-748.
50. Mucchiano GI, Haggqvist B, Sletten K, Westermark P, (2001) Apolipoprotein A-1-derived amyloid in atherosclerotic plaques of the human aorta. J Pathol 193: 270-275.
51. Vollmer E, Brust J, Roessner A, Bosse A, Burwikel F, et al. (1991) Distribution patterns of apolipoproteins A1, A2, and B in the wall of atherosclerotic vessels. Virchows Arch A Pathol Anat Histopathol 419: 79-88.
52. Nichols WC, Dwulet FE, Liepnieks J, Benson MD, (1988) Variant apolipoprotein AI as a major constituent of a human hereditary amyloid. Biochem Biophys Res Commun 156: 762-768.
53. Nichols WC, Gregg RE, Brewer HB Jr, Benson MD, (1990) A mutation in apolipoprotein A-I in the Iowa type of familial amyloidotic polyneuropathy. Genomics 8: 318-323.
54. Testro AG, Brennan SO, Macdonell RA, Hawkins PN, Angus PW, (2007) Hereditary amyloidosis with progressive peripheral neuropathy associated with apolipoprotein AI Gly26Arg: outcome of hepatorenal transplantation. Liver Transpl 13: 1028-1031.
55. Gursky O, Mei X, Atkinson D, (2012) The crystal structure of the C-terminal truncated apolipoprotein A-I sheds new light on amyloid formation by the N-terminal fragment. Biochemistry 51: 10-18.
56. Merlini G, Bellotti V, (2003) Molecular mechanisms of amyloidosis. N Engl J Med 349: 583-596.
57. Paula-Lima AC, Tricerri MA, Brito-Moreira J, Bomfim TR, Oliveira FF, et al. (2009) Human apolipoprotein A-I binds amyloid-beta and prevents Abeta-induced neurotoxicity. Int J Biochem Cell Biol 41: 1361-1370.
58. Zhang W, Wang T, Pei Z, Miller DS, Wu X, et al. (2005) Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. Faseb J 19: 533-542.